Interaction of Body Mass Index and Diabetes as Modifiers of Cardiovascular Mortality in a Cohort Study

Seung Hyun Ma1,2, Bo-Young Park1, Jae Jeong Yang1,2, En-Joo Jung1, Yohwan Yeo1, Yungi Whang1,4, Soung-Hoon Chang3, Hai-Rim Shin6, Daehee Kang1,2,4, Keun-Young Yoo1, Sue Kyung Park1,2,4

1Department of Preventive Medicine, Seoul National University College of Medicine, Seoul; 2Cancer Research Institute, Seoul National University, Seoul; 3Cancer Epidemiology Branch, National Cancer Center, Goyang; 4Department of Biomedical Science, Seoul National University Graduate School, Seoul; 5Department of Preventive Medicine, Konkuk University School of Medicine, Chungju, Korea; 6Non-communicable Disease and Health Promotion, Western Pacific Regional Office, World Health Organization, Manila, Philippines

Objectives: Diabetes and obesity each increases mortality, but recent papers have shown that lean Asian persons were at greater risk for mortality than were obese persons. The objective of this study is to determine whether an interaction exists between body mass index (BMI) and diabetes, which can modify the risk of death by cardiovascular disease (CVD).

Methods: Subjects who were over 20 years of age, and who had information regarding BMI, past history of diabetes, and fasting blood glucose levels (n = 16 048), were selected from the Korea Multi-center Cancer Cohort study participants. By 2008, a total of 1290 participants had died; 251 and 155 had died of CVD and stroke, respectively. The hazard for deaths was calculated with hazard ratio (HR) and 95% confidence interval (95% CI) by Cox proportional hazard model.

Results: Compared with the normal population, patients with diabetes were at higher risk for CVD and stroke deaths (HR, 1.84; 95% CI, 1.33 to 2.56; HR, 1.82; 95% CI, 1.20 to 2.76; respectively). Relative to subjects with no diabetes and normal BMI (21 to 22.9 kg/m²), lean subjects with diabetes (BMI < 21 kg/m²) had a greater risk for CVD and stroke deaths (HR, 2.83; 95% CI, 1.57 to 5.09; HR, 3.27; 95% CI, 1.58 to 6.76; respectively), while obese subjects with diabetes (BMI ≥ 25 kg/m²) had no increased death risk (p-interaction < 0.05). This pattern was consistent in sub-populations with no incidence of hypertension.

Conclusions: This study suggests that diabetes in lean people is more critical to CVD deaths than it is in obese people.

Key words: Diabetes mellitus, Body mass index, Cardiovascular diseases, Mortality

INTRODUCTION

Diabetes is one of the most rapidly increasing public health issues. The prevalence rate of diabetes is expected to show a continual increase from 2.8% in 2000 to 4.4% in 2030, and the rate of increase will be higher in developing countries than in developed countries [1]. In South Korea, the prevalence rate in adults 30 years of age and older has rapidly increased from 1% to 4% in the 1970s to 9.5% in 2007 (the National Nutrition Survey [2]).

Obesity is an independent risk factor for diabetes [3]. Although insulin secretion is increased in obese persons, insulin action is decreased; these are the clinical conditions of type 2 diabetes [4,5]. Obesity is consistently associated with an increased risk in
all causes of mortality, and particularly with cardiovascular disease (CVD), including ischemic heart diseases [6-9]. Diabetes is also associated with an increased risk for all-cause and CVD deaths [10]. Obesity is a risk factor for both diabetes and cardiovascular morbidity and mortality; therefore, the direct association between body mass index (BMI) and cardiovascular mortality observed in the general population might be expected. Persons with both disorders are expected to be at a higher risk for death relative to normal persons without both disorders because both factors are risk factors for CVD death. However, the combined effect of diabetes and obesity for CVD mortality may be more complicated and may generate results that are different from these simple expectations.

This study was designed to explore the combined effects of weight status and diabetes on cardiovascular mortality in prospective cohort study.

METHODS

Study Population and Data Collection
The study population was selected from the Korean Multicenter Cancer Cohort (KMCC), a community-based prospective cohort, and from participants recruited from urban and rural areas in Korea (Haman, Chungju, Uljin, and Youngil). The KMCC is described in more depth in a previous study [11].

We excluded 2361 of the KMCC participants whose enrollment age was under 20 years; 1527 who had no fasting blood glucose (FBG) levels, and 79 with no past medical history for diabetes. We ultimately analyzed 16 048 individuals in this study. By December 31, 2008, the total person-years were 147 296 person-years, and the median follow-up duration was 9.41 years.

Information on general lifestyle, anthropometric measurements, diet, cigarette smoking, alcohol consumption, reproductive factors, and other environmental factors were obtained using structured questionnaire interviews. Anthropometric indices (height, weight, etc.) were measured directly using standard methods during the baseline physical examination. Weight and height were measured to the nearest 0.5 kg and 0.5 cm, respectively. BMI was calculated as weight (kg)/height (m²) and was categorized as <21, 21 to 22.9, 23 to 24.9, and ≥25 kg/m² [12]. Blood was collected after overnight fasting to determine FBG levels.

The study protocol for the KMCC was approved by the institutional review boards of Seoul National University and the National Cancer Center of Korea (H0110-084-002, C-1012-082-344).

Definition of Main Exposure and Outcome Variables
We used a combined definition that incorporated the past diagnosis of diabetes and the FBG levels at enrollment. Participants with diabetes were classified as patients having known diabetes mellitus (i.e., patients diagnosed as diabetic in a hospital or having undergone previous treatment for diabetes) or FBG ≥126 mg/dL. Participants with impaired glucose tolerance (IGT) were defined as having FBG levels of 100 to 125 mg/dL and no past history of diabetes. Those with ‘No diabetes’ was defined as having FBG levels of no more than 100 mg/dL and no past history of diabetes [13].

Overweight and obesity were defined by the World Health Organization (WHO) Asia-Pacific Guideline (overweight, 23 ≤ BMI < 25 kg/m²; obesity, BMI > 25 kg/m²). Optimum BMI levels were defined as a BMI of 21 to 22.9 kg/m², based on a WHO expert consultation report [12] and BMI <21 kg/m² was defined as underweight in this study population.

We classified the cause of death according to the International Classification of Disease 10th revision (ICD-10). We used the national death certificate database and merged death certificate data until December 31, 2008. Deaths were divided into those resulting from CVD (ICD-10 codes I00-I99) [14], diseases of the heart (ICD-10 codes I00-I09, I11, I13, I20-I51), and stroke (ICD-10 codes I60-I69) [15].

Statistical Analysis
Differences in means and proportions for baseline characteristics of the combined definition of past diagnosis of diabetes mellitus (DM) and FBG were tested using 1-way ANOVA and chi-square analyses, respectively. The Cox proportional hazards regression was used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) for CVD mortality. Co-linearity between covariates was examined by calculating the mean and individual covariate variance inflation factors. None of the individual covariate variance inflation factors was greater than 1.5 and the mean variance inflation factor for all covariates included in the CVD models was 1.03. The assumption that each predictor affects mortality proportionally over the entire follow-up period was examined using graphical methods and was found to be reasonable for all the predictors considered here. The significance of the explanatory variables in-
cluded in the Cox models was computed by the likelihood-ratio test. Tests for trend were performed by using the ordered category as a continuous variable in the proportional hazard model.

We evaluated whether the association between diabetes and mortality was modified by obesity. The group with normal BMI (21 to 22.9) and no diabetes were chosen as a reference, to look into mortality according to the joint classification of BMI and the defined combination of past diagnosis of DM and FBG. We used the Cox regression model to test for an interaction the diabetes group and obesity group. To test an interaction, we performed the analysis including diabetes group, obesity group and multiplicative interaction terms of both. Statistical significance of interaction was assumed at a \( p \)-value of 0.05 or smaller.

Since cigarette smoking [16], alcohol consumption [17], and hypertension [18] are associated with higher risk for CVD deaths, we re-evaluated the combined effect between diabetes and BMI in the group without these three major risk factors. Analyses were done with SAS version 9.2 (SAS Institute Inc., Cary, NC, USA).

RESULTS

Selected characteristics of the subjects are presented in Table 1. A total of 16 048 people were subjects of the analysis, with 60% females, and the total mean age was 55.7 years of age. At baseline (1993), subjects with diabetes were associated with greater age, higher levels of BMI, smoking status, and history of hypertension, but with a lower likelihood of being female, having a high education status, or alcohol drinking.

Table 2 shows the HRs (95% CIs) of diabetes and IGT for CVD mortality, relative to the normal population without IGT and diabetes, in the KMCC cohort study subjects from 1993 to 2008. The hazard for CVD death was increased from that of the normal population by having diabetes or IGT (\( p < 0.001 \)). Compared to the normal population, subjects with diabetes had a 1.84-fold higher risk of CVD death (95% CI, 1.33 to 2.56). The hazard for heart disease and stroke also showed an increasing trend from the normal population to the IGT group to the diabetes groups (p-trend, 0.09 and 0.01, respectively). Diabetes was associated with a 1.84-fold and a 1.82-fold higher risk for

| Table 1. General characteristics of the study population at the time of recruitment |
|---------------------------------|----------|----------|----------|-----|
|                                | Normal population (n=11,791) | Subjects with IGT (n=2545) | Subjects with diabetes (n=1712) | \( p \)-value |
| Age (years)                    | 55.4 (12.1) | 56.0 (12.4) | 57.1 (11.8) | <0.001 |
| Body mass index (kg/m\(^2\))  | 23.5 (3.3) | 23.6 (3.3) | 24.3 (3.4) | <0.001 |
| Duration of follow-up (y)     | 9.0 (3.4)  | 9.8 (4.1)  | 9.2 (4.0)  | <0.001 |
| Female                         | 60.4      | 58.6      | 58.1      | 0.07 |
| Educated                       | 78.8      | 74.1      | 71.6      | <0.001 |
| Current smoker                 | 27.4      | 28.4      | 28.5      | 0.03 |
| Current drinker                | 38.0      | 37.3      | 35.6      | 0.006 |
| History of hypertension        | 9.9       | 12.4      | 19.6      | <0.001 |

Values are presented as mean (SD) or %. IGT, impaired glucose tolerance.

Table 2. HRs (95% CIs) of diabetes and IGT for cardiovascular disease mortality relative to normal population without IGT and diabetes in the KMCC cohort population from 1993 to 2008

| Person-year | No. of deaths | HR (95% CI)\(^1\) | HR (95% CI)\(^2\) |
|-------------|---------------|--------------------|--------------------|
| Cardiovascular disease mortality\(^3\) | Normal 106 657 161 | 1.00 (reference) | 1.00 (reference) |
| IGT 24 849 41 | 1.09 (0.77, 1.54) | 1.05 (0.74, 1.49) |
| Diabetes 15 788 49 | 1.92 (1.39, 2.64) | 1.84 (1.33, 2.56) |
| \( p \)-trend | <0.001 | <0.001 |
| Heart disease mortality\(^4\) | Normal 106 657 50 | 1.00 (reference) | 1.00 (reference) |
| IGT 24 849 13 | 1.06 (0.57, 1.94) | 1.00 (0.54, 1.85) |
| Diabetes 15 788 15 | 1.93 (1.10, 3.38) | 1.84 (1.04, 3.25) |
| \( p \)-trend | 0.07 | 0.09 |
| Stroke mortality\(^5\) | Normal 106 657 99 | 1.00 (reference) | 1.00 (reference) |
| IGT 24 849 26 | 1.14 (0.74, 1.75) | 1.09 (0.71, 1.69) |
| Diabetes 15 788 30 | 1.92 (1.27, 2.89) | 1.82 (1.20, 2.76) |
| \( p \)-trend | 0.008 | 0.01 |
| Other cardiovascular disease mortality\(^6\) | Normal 106 657 10 | 1.00 (reference) | 1.00 (reference) |
| IGT 24 849 2 | 0.86 (0.19, 3.92) | 0.89 (0.19, 4.17) |
| Diabetes 15 788 3 | 1.85 (0.51, 6.71) | 1.82 (0.49, 6.81) |
| \( p \)-trend | 0.60 | 0.63 |

HR, hazard ratio; CI, confidence interval; IGT, impaired glucose tolerance; KMCC, Korean Multi-center Cancer Cohort; ICD-10, International Classification of Disease 10th revision.

\(^1\)Adjusted for age (5-year categories).

\(^2\)Adjusted for age (5-year categories), gender, educational attainment (high school graduate versus more, cigarette smoking (never, current, and past), alcohol consumption (never, current, and past), past history of hypertension (yes/no) and body mass index (<21, 21-22.9, 23-24.9, ≥25).

\(^3\)ICD-10 codes of I00-I99.

\(^4\)ICD-10 codes of I00-I09, I11, I13, I20-I51.

\(^5\)ICD-10 codes of I60-I69.

\(^6\)ICD-10 codes of I10, I12, I14-I19, I52-59, and I70-I99.
Table 3. Hazard ratios (95% confidence intervals) of each category of diabetes and BMI for cardiovascular disease mortality relative to normal population without IGT, diabetes, and with optimal BMI levels in the KMCC cohort population from 1993 to 2008.

| BMI     | Person-year | No. of deaths | Normal   | No. of deaths | IGT       | No. of deaths | Diabetes | Hazard ratio (95% CI) | p-interaction |
|---------|-------------|---------------|----------|---------------|-----------|---------------|----------|-----------------------|--------------|
| < 21    | 30,012      | 34            | 0.88 (0.56, 1.40) | 11           | 1.02 (0.52, 1.99) | 16           | 2.83 (1.57, 5.09) | 0.02        |
| 21-22.9 | 32,823      | 39            | 1.00 (reference) | 10           | 0.98 (0.49, 1.97) | 12           | 2.10 (1.09, 4.02) | 0.012       |
| 23-24.9 | 32,736      | 32            | 0.91 (0.57, 1.46) | 6            | 0.67 (0.29, 1.59) | 6            | 1.17 (0.49, 2.77) | 0.709       |
| ≥ 25    | 42,004      | 49            | 1.09 (0.71, 1.68) | 13           | 1.30 (0.69, 2.45) | 12           | 1.15 (0.60, 2.21) | 0.300       |

Heart disease mortality:

| BMI     | Person-year | No. of deaths | Normal   | No. of deaths | IGT       | No. of deaths | Diabetes | Hazard ratio (95% CI) | p-interaction |
|---------|-------------|---------------|----------|---------------|-----------|---------------|----------|-----------------------|--------------|
| < 21    | 30,012      | 12            | 0.91 (0.41, 2.01) | 4            | 1.07 (0.35, 3.31) | 4            | 2.17 (0.70, 6.73) | 0.71        |
| 21-22.9 | 32,823      | 13            | 1.00 (reference) | 5            | 1.44 (0.51, 4.08) | 4            | 2.03 (0.66, 6.25) | 0.193       |
| 23-24.9 | 32,736      | 9             | 0.77 (0.33, 1.79) | 2            | 0.67 (0.15, 2.96) | 2            | 1.28 (0.29, 5.71) | 0.007       |
| ≥ 25    | 42,004      | 16            | 1.16 (0.56, 2.43) | 2            | 0.62 (0.14, 2.75) | 5            | 1.43 (0.51, 4.04) | 0.03        |

Stroke mortality:

| BMI     | Person-year | No. of deaths | Normal   | No. of deaths | IGT       | No. of deaths | Diabetes | Hazard ratio (95% CI) | p-interaction |
|---------|-------------|---------------|----------|---------------|-----------|---------------|----------|-----------------------|--------------|
| < 21    | 30,012      | 20            | 0.89 (0.49, 1.63) | 7            | 1.12 (0.48, 2.63) | 11           | 3.27 (1.58, 6.76) | 0.03        |
| 21-22.9 | 32,823      | 23            | 1.00 (reference) | 4            | 0.67 (0.23, 1.95) | 8            | 2.43 (1.08, 5.44) | 0.007       |
| 23-24.9 | 32,736      | 22            | 1.06 (0.59, 1.91) | 4            | 0.77 (0.28, 2.21) | 3            | 0.95 (0.28, 3.16) | 0.007       |
| ≥ 25    | 42,004      | 29            | 1.12 (0.64, 1.94) | 10           | 1.89 (0.79, 3.56) | 6            | 0.98 (0.39, 2.42) | 0.007       |

BMI, body mass index; IGT, impaired glucose tolerance; KMCC, Korean Multi-center Cancer Cohort; ICD-10, International Classification of Disease 10th revision.
1Adjusted for age (5-year categories), gender, educational attainment (high school graduate versus more), cigarette smoking (never, current, and past), alcohol consumption (never, current, and past) and past history of hypertension (yes/no).
2ICD-10 codes of I00-I09.
3ICD-10 codes of I00-I09, I11, I13, I20-I51.
4ICD-10 codes of I60-I69.

Table 3 shows the HRs (95% CIs) for each category of diabetes and BMI for cardiovascular disease mortality, relative to the normal population without IGT, diabetes, and with optimal BMI levels, in the KMCC cohort study subjects from 1993 to 2008. Relative to diabetic subjects having optimal BMI levels and no IGT, the underweight diabetes group had a higher risk of CVD death (HR, 2.83; 95% CI, 1.57 to 5.09), whereas the obese diabetes group had a risk for CVD death similar to the reference group (HR, 1.15; 95% CI, 0.60 to 2.21). The risk for CVD death differed according to the presence of obesity and diabetes (p-for interaction, 0.012). Heart disease and stroke mortality also showed similar results. The hazard ratio of the underweight diabetes group was highest for heart disease and stroke (HR, 2.17; 95% CI, 0.70 to 6.73; HR, 3.27; 95% CI, 1.58 to 6.76; respectively). On the other hand, the obese diabetes group did not show any differences in heart disease and stroke mortality compared to the reference group (HR, 1.43; 95% CI, 0.51 to 4.04; HR, 0.98; 95% CI, 0.39 to 2.42; respectively). With respect to stroke mortality, the BMI and diabetes status showed a significant interaction (p-for interaction, 0.025); however, for heart disease mortality, no interaction was apparent (p-for interaction, 0.709).

Table 4 shows the HRs (95% CIs) for each category of diabetes and BMI for CVD mortality, relative to the normal population without IGT or diabetes and with optimal BMI levels, among nonsmokers, nondrinkers, and subjects without hypertension history. Among nondrinkers and subjects without hypertension history, the risk for CVD and stroke mortality was significantly increased in the underweight diabetes group when compared to the reference group (for CVD: HR, 2.84; 95% CI, 1.26 to 6.38 and HR, 3.10; 95% CI, 1.72 to 5.61; for stroke: HR, 3.81; 95% CI, 1.44 to 10.99 and HR, 3.75; 95% CI, 1.79 to 7.84; respectively). Among nonsmokers, the risk elevation in the underweight diabetes group was maintained, although not statistically significant. In contrast, the risk for CVD and stroke was concurrently decreased in both the underweight non-diabetes and the non-IGT and obese diabetes groups without hypertension history (p-for interaction, 0.004 for CVD death; 0.012 for stroke death), although not statistically significant.

We shows that each of the three diabetes groups showed an increased hazard ratio as BMI decreased, when compared to the obese group (data are not shown). The normal and IGT groups showed no change in all mortality, while in the diabe-
Table 4. Hazard ratios (95% confidence intervals) of each category of diabetes and BMI for cardiovascular disease mortality among subjects without cigarette smoking, alcohol consumption, or hypertension in the KMCC cohort population from 1993 to 2008.

| Person-year | No. of deaths | Normal | IGT | Diabetes | p-interaction |
|-------------|---------------|--------|-----|----------|---------------|
| Cardiovascular disease mortality<sup>1</sup> | | | | | | |
| Nonsmokers<sup>2</sup> | | | | | | |
| BMI | | | | | | |
| <21 | 14 890 | 26 | 0.85 (0.47, 1.52) | 0.35 (0.08, 1.48) | 1.92 (0.74, 5.00) | 0.44 |
| 21-22.9 | 19 552 | 41 | 1.00 (reference) | 0.83 (0.38, 2.26) | 1.65 (0.72, 3.79) | |
| 23-24.9 | 21 291 | 29 | 0.71 (0.40, 1.26) | 0.74 (0.29, 1.92) | 0.89 (0.27, 2.92) | |
| ≥25 | 30 424 | 56 | 0.95 (0.58, 1.57) | 1.21 (0.59, 2.50) | 1.03 (0.49, 2.19) | |
| Nondrinkers<sup>3</sup> | | | | | | |
| BMI | | | | | | |
| <21 | 16 167 | 34 | 1.05 (0.59, 1.88) | 0.52 (0.16, 1.75) | 2.84 (1.26, 6.38) | 0.12 |
| 21-22.9 | 18 115 | 37 | 1.00 (reference) | 1.11 (0.45, 2.73) | 1.95 (0.84, 4.56) | |
| 23-24.9 | 19 126 | 27 | 0.91 (0.49, 1.65) | 0.74 (0.26, 2.15) | 1.07 (0.32, 3.57) | |
| ≥25 | 26 012 | 52 | 1.19 (0.70, 2.04) | 1.69 (0.83, 3.49) | 1.02 (0.44, 2.38) | |
| Subjects without hypertension history<sup>4</sup> | | | | | | |
| BMI | | | | | | |
| <21 | 28 470 | 55 | 0.68 (0.41, 1.12) | 1.07 (0.54, 2.10) | 3.10 (1.72, 5.61) | 0.004 |
| 21-22.9 | 30 423 | 57 | 1.00 (reference) | 0.86 (0.39, 1.84) | 2.04 (1.04, 4.01) | |
| 23-24.9 | 29 585 | 36 | 0.74 (0.44, 1.23) | 0.74 (0.31, 1.76) | 1.23 (0.49, 3.15) | |
| ≥25 | 35 518 | 55 | 0.97 (0.61, 1.54) | 1.32 (0.67, 2.59) | 0.82 (0.37, 1.84) | |
| Stroke mortality<sup>5</sup> | | | | | | |
| Nonsmokers<sup>2</sup> | | | | | | |
| BMI | | | | | | |
| <21 | 14 890 | 16 | 0.92 (0.42, 2.01) | 0.33 (0.04, 2.51) | 2.89 (0.96, 8.79) | 0.42 |
| 21-22.9 | 19 552 | 22 | 1.00 (reference) | 0.87 (0.25, 3.01) | 1.77 (0.59, 5.36) | |
| 23-24.9 | 21 291 | 21 | 1.07 (0.53, 2.16) | 1.13 (0.38, 3.42) | 0.54 (0.07, 4.07) | |
| ≥25 | 30 424 | 33 | 1.01 (0.52, 1.97) | 1.78 (0.75, 4.22) | 1.08 (0.39, 2.97) | |
| Nondrinkers<sup>3</sup> | | | | | | |
| BMI | | | | | | |
| <21 | 16 167 | 20 | 1.05 (0.49, 2.28) | 0.31 (0.04, 2.39) | 3.81 (1.44, 10.09) | 0.14 |
| 21-22.9 | 18 115 | 18 | 1.00 (reference) | 0.65 (0.15, 2.90) | 1.49 (0.43, 5.26) | |
| 23-24.9 | 19 126 | 21 | 1.28 (0.62, 2.66) | 0.98 (0.28, 3.47) | 1.23 (0.28, 5.48) | |
| ≥25 | 26 012 | 31 | 1.28 (0.63, 2.57) | 2.17 (0.89, 5.23) | 0.77 (0.22, 2.71) | |
| Subjects without hypertension with diabetes<sup>4</sup> | | | | | | |
| BMI | | | | | | |
| <21 | 28 470 | 34 | 0.74 (0.39, 1.42) | 1.24 (0.53, 2.93) | 3.75 (1.79, 7.84) | 0.012 |
| 21-22.9 | 30 423 | 31 | 1.00 (reference) | 0.58 (0.17, 1.93) | 2.37 (1.04, 5.58) | |
| 23-24.9 | 29 585 | 23 | 0.92 (0.49, 1.75) | 0.89 (0.31, 2.59) | 0.86 (0.20, 3.68) | |
| ≥25 | 35 518 | 34 | 1.03 (0.56, 1.88) | 1.75 (0.77, 3.95) | 1.07 (0.40, 2.84) | |

BMI, body mass index; KMCC, Korean Multi-center Cancer Cohort; IGT, impaired glucose tolerance; ICD-10, International Classification of Disease 10th revision.  
<sup>1</sup>ICD-10 codes of I00-I99.  
<sup>2</sup>Adjusted for age (5-year categories), gender, educational attainment (high school graduate versus more), alcohol consumption (never, current, and past) and past history of hypertension (yes/no).  
<sup>3</sup>Adjusted for age (5-year categories), gender, educational attainment (high school graduate versus more), cigarette smoking (never, current, and past) and past history of hypertension (yes/no).  
<sup>4</sup>Adjusted for age (5-year categories), gender, educational attainment (high school graduate versus more), cigarette smoking (never, current, and past) and alcohol consumption (never, current, and past).  
<sup>5</sup>ICD-10 codes of I60-I69.

test group, CVD and stroke mortality increased in the underweight group (HR, 2.34; 95% CI, 1.06 to 5.19; HR, 2.99; 95% CI, 1.01 to 8.58; respectively).

DISCUSSION

In this prospective cohort study, we found that lean persons (BMI <21 kg/m²) with diabetes had at an elevated risk for CVD death, whereas obese persons (BMI ≥25 kg/m²) with diabetes
had no elevated risk for death. These results are consistent in a hypertension-free population; a similar pattern is found in nonsmokers and nondrinkers, despite a lack of statistical significance due to the small sample size.

Some recent studies match the conclusion of our study [19]. However, BMI and CVD mortality with respect to diabetes currently show a variety of results, including positive [20,21], inverse [22], and null [23] associations. For example, the study by Batty et al. [20], which targeted only Caucasian males, indicated that the diabetes group shows an increased CVD mortality as BMI increases. However, a different study that compared BMI and CVD mortality in White and African-American males showed different results [24]. A study by Khalingot et al. [21], which targeted patients with diabetes, indicated an increased mortality in the underweight group, no increased mortality in class I obesity (BMI, 30 to 34.9), similar to our results, however a severely obese group (BMI ≥ 35) showed increased mortality. However, these findings have low comparability with our study since the study was focused on Ukrainian people.

A study by Weiss et al. [22] indicated a decreased mortality in patients with diabetes as their weight increased. It is difficult to apply the findings of this study to our study, or to generalize the results, since the study was focused on an elderly, hospitalized population. A study by Nilsson et al. [19], which targeted the general population group, indicated that the cause of mortality as an outcome was a combined effect of diabetes and BMI, similar to the findings of our study, but no analysis of CVD mortality was possible because the targeted number of patients was only 432 people. Generalization to the entire population was also difficult since this study was focused on a population group consisting of people over 75 years old.

The findings of the present study show interaction of BMI and diabetes to modify cardiovascular mortality in sub-populations without cigarette smoking, alcohol drinking or hypertension. Our results also indicated that subjects without hypertension history were consistent. However, nonsmokers and non-drinker groups tended to be consistent but the results were not statistically different from the main results of the present study. In the case of smoking and drinking, Nonsmokers and non-drinker groups had more deaths resulting from causes other than CVD and stroke mortality. The obesity paradox implies paradoxically decreased mortality in association with increasing BMI up to and including obesity and has been reported among patients with hypertension [25]. To our results, a combined effect of BMI and diabetes could modify CVD and stroke mortality without the obesity paradox effect of hypertension.

In the general population, obesity is a risk factor for both diabetes and CVD mortality [26,27]. A positive association between obesity and CVD mortality has also been identified in individuals with coronary heart disease at baseline [28]. Therefore, the lack of an association between increasing BMI and CVD mortality observed in the present study seemed counterintuitive.

We suggest several explanations for the protective effect of elevated BMI on mortality in subjects with diabetes. For example, overweight may reflect the protective effects of increased energy stores. In end-stage renal disease patients, protein-energy wasting and inflammation contribute to elevated mortality and underpin the direct association observed between BMI and survival [29,30]. The increased energy stores in subjects with diabetes who also have elevated BMI may therefore protect them from similar energy wasting and inflammation. Indeed, adipose tissue acts as a buffer against malnutrition and may represent an evolutionary survival advantage [31].

Our study has some limitations. For example, BMI was measured on only a single occasion. As such, the potential impact of weight change over time cannot be assessed. Therefore, obese or overweight people who lost weight may have altered their survival. A second possibility is that the lowest BMI values in the present study may possibly have resulted from a catabolic process and did not reflect long-term thinness. Subjects with less than one year of follow up were omitted from the analysis, to minimize the impact of this possibility. Another limitation is that the use of self-reported information prevented us from distinguishing between the two types of the disease. The possibility of weight loss after diagnosis of diabetes (mainly of type 1) would result in an underestimate of the role of BMI in determining the risk of the disease. However, the prevalence of type 1 diabetes is substantially lower than that of type 2 diabetes in this region [32,33] and type 1 diabetes also increases CVD mortality [34] so that an inability to distinguish between types of diabetes probably does not substantially affect the interpretation of the results. The use of self-reported diabetes may also represent some measurement error; however, studies conducted in community-based populations have found self-reported diabetes to be moderately to highly accurate in determining disease status [35].

Nonetheless, the present study has the following merits. First, it can clearly identify the timing of the findings according to a
population based prospective cohort and it indicates a decreased possibility of bias resulting in potential confounding variables due to memory, according to the survey data. In addition, the median length of follow-up was 9.4 years (25 to 75 percentile; 5.8 to 11.6 years), which provided relatively good statistical power.

The present investigation demonstrates that lean people with diabetes constitute a high-risk group for CVD mortality. No similar effect on CVD mortality is seen in overweight or obese people, either with or without diabetes. These observations can have important clinical implications because they indicate that in lean people with diabetes might have a worse prognostic significance than in normal and obese people with diabetes or without diabetes.

ACKNOWLEDGEMENTS

This research was supported by Basic Research Laboratory program through the National Research Foundation of Korea funded by the Ministry of Education, Science and Technology (2012-0000347).

CONFLICT OF INTEREST

The authors have no conflicts of interest with the material presented in this paper.

REFERENCES

1. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004;27(5):1047-1053.
2. The Korea Centers for Disease Control and Prevention. Korean National Health and Nutrition Examination Survey [cited 2012 Nov 19]. Available from: http://knhanes.cdc.go.kr/knhanes (Korean).
3. Wilson PW, Meigs JB, Sullivan L, Fox CS, Nathan DM, D’Agostino RB Sr. Prediction of incident diabetes mellitus in middle-aged adults: the Framingham Offspring Study. Arch Intern Med 2007;167(10):1068-1074.
4. Boffetta P, McLerran D, Chen Y, Inoue M, Sinha R, He J, et al. Body mass index and diabetes in Asia: a cross-sectional pooled analysis of 900,000 individuals in the Asia cohort consortium. PLoS One 2011;6(6):e19930.
5. Mokdad AH, Ford ES, Bowman BA, Dietz WH, Vinicor F, Bales VS, et al. Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA 2003;289(1):76-79.
6. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 2003;348(17):1625-1638.
7. Calle EE, Thun MJ, Petrelli JM, Rodriguez C, Heath CW Jr. Body mass index and mortality in a prospective cohort of U.S. adults. N Engl J Med 1999;341(15):1097-1105.
8. Prospective Studies Collaboration, Whittlock G, Lewington S, Sherliker P, Clarke R, Emberson J, et al. Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies. Lancet 2009;373(9669):1083-1096.
9. Zheng W, McLerran DF, Rolland B, Zhang X, Inoue M, Matsuo K, et al. Association between body-mass index and risk of death in more than 1 million Asians. N Engl J Med 2011;364(8):719-729.
10. Barr EL, Zimmet PZ, Welborn TA, Jolley D, Magliano DJ, Dunstan DW, et al. Risk of cardiovascular and all-cause mortality in individuals with diabetes mellitus, impaired fasting glucose, and impaired glucose tolerance: the Australian Diabetes, Obesity, and Lifestyle Study (AusDiab). Circulation 2007;116(2):151-157.
11. Yoo KY, Shin HR, Chang SH, Lee KS, Park SK, Kang D, et al. Korean Multi-center Cancer Cohort Study including a Biological Materials Bank (KMCC-I). Asian Pac J Cancer Prev 2002;3(1):85-92.
12. WHO Expert Consultation. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet 2004;363(9403):157-163.
13. The Committee of the Japan Diabetes Society on the Diagnostic Criteria of Diabetes Mellitus, Seino Y, Nanjo K, Tajima N, Kadowaki T, Kashiwagi A, et al. Report of the committee on the classification and diagnostic criteria of diabetes mellitus. J Diabetes Invest 2010;1(5):212-228.
14. Kokkinos P, Myers J, Faselis C, Doumas M, Kheirbek R, Nylen E. BMI-mortality paradox and fitness in African American and Caucasian men with type 2 diabetes. Diabetes Care 2012;35(5):1021-1027.
15. Jerant A, Franks P. Body mass index, diabetes, hypertension, and short-term mortality: a population-based observational study, 2000-2006. J Am Board Fam Med 2012;25(4):422-431.
16. Qiao Q, Tervahauta M, Nissinen A, Tuomilehto J. Mortality from all causes and from coronary heart disease related to smoking
and changes in smoking during a 35-year follow-up of middle-aged Finnish men. Eur Heart J 2000;21(19):1621-1626.
17. Di Castelnuovo A, Costanzo S, Bagnardi V, Donati MB, Iacoviello L, de Gaetano G. Alcohol dosing and total mortality in men and women: an updated meta-analysis of 34 prospective studies. Arch Intern Med 2006;166(22):2437-2445.
18. Dahlöf B, Lindholm LH, Hansson L, Scherstén B, Ekborn T, Wester PO. Morbidity and mortality in the Swedish trial in old patients with hypertension (STOP-Hypertension). Lancet 1991;338(8778):1281-1285.
19. Nilsson G, Hedberg P, Öhrvik J. Survival of the fattest: unexpected findings about hyperglycaemia and obesity in a population based study of 75-year-olds. BMJ Open 2011;1(1):e000012.
20. Batty GD, Kivimaki M, Smith GD, Marmot MG, Shipley MJ. Obesity and overweight in relation to mortality in men with and without type 2 diabetes/impaired glucose tolerance: the original Whitehall Study. Diabetes Care 2007;30(9):2388-2391.
21. Khalangot M, Tronko M, Kravchenko V, Kulchinska J, Hu G. Body mass index and the risk of total and cardiovascular mortality among patients with type 2 diabetes: a large prospective study in Ukraine. Heart 2009;95(6):454-460.
22. Weiss A, Boaz M, Beloosesky Y, Kornowski R, Grossman E. Body mass index and risk of all-cause and cardiovascular mortality in hospitalized elderly patients with diabetes mellitus. Diabet Med 2009;26(3):253-259.
23. So WY, Yang X, Ma RC, Kong AP, Lam CW, Ho CS, et al. Risk factors in V-shaped risk associations with all-cause mortality in type 2 diabetes-The Hong Kong Diabetes Registry. Diabetes Metab Res Rev 2008;24(3):238-246.
24. Abell JE, Egan BM, Wilson PW, Lipsitz S, Woolson RF, Lackland DT. Differences in cardiovascular disease mortality associated with body mass between Black and White persons. Am J Public Health 2008;98(1):63-66.
25. Uretsky S, Messerli FH, Bangalore S, Champion A, Cooper-Dehoff RM, Zhou Q, et al. Obesity paradox in patients with hypertension and coronary artery disease. Am J Med 2007;120(10):863-870.
26. Avenell A; National Co-ordinating Center for HTA. Systematic review of the long-term effects and economic consequences of treatments for obesity and implications for health improvement. York: York Publishing; 2004, P. 1-182.
27. Morales DD, Punzalan FE, Paz-Pacheco E, Sy RG, Duante CA; National Nutrition And Health Survey: 2003 Group. Metabolic syndrome in the Philippine general population: prevalence and risk for atherosclerotic cardiovascular disease and diabetes mellitus. Diab Vasc Dis Res 2008;5(1):36-43.
28. Batty GD, Shipley MJ, Jarrett RJ, Breeze E, Marmot MG, Davey Smith G. Obesity and overweight in relation to disease-specific mortality in men with and without existing coronary heart disease in London: the original Whitehall study. Heart 2006;92(7):886-892.
29. Kalantar-Zadeh K, Stenvinkel P, Pillon L, Kopple JD. Inflammation and nutrition in renal insufficiency. Adv Ren Replace Ther 2003;10(3):155-169.
30. Kopple JD. How to reconcile conventional and altered risk factors patterns in dialysis patients. Semin Dial 2007;20(6):602-605.
31. Wells JC. The evolution of human fatness and susceptibility to obesity: an ethological approach. Biol Rev Camb Philos Soc 2006;81(2):183-205.
32. Karvonen M, Viik-Kajander M, Moltchanova E, Libman I, Laporte R, Tuomilehto J. Incidence of childhood type 1 diabetes worldwide. Diabetes Mondiale (DiaMond) Project Group. Diabetes Care 2000;23(10):1516-1526.
33. Ahn KJ. Is diabetes in Korea different? J Korean Med Assoc 2005;48(8):707-714.
34. Secrest AM, Becker DJ, Kelsey SF, Laporte RE, Orchard TJ. Cause-specific mortality trends in a large population-based cohort with long-standing childhood-onset type 1 diabetes. Diabetes 2010;59(12):3216-3222.
35. Okura Y, Urban LH, Mahoney DW, Jacobsen SJ, Rodeheffer RJ. Agreement between self-report questionnaires and medical record data was substantial for diabetes, hypertension, myocardial infarction and stroke but not for heart failure. J Clin Epidemiol 2004;57(10):1096-1103.